Alkermes Plc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.alkermes.com

Earnings Score
Moat Score
Safety Score

Market Cap $5.11B
PE 15
Debt $288.82M
Cash $396.29M
EV $5.01B
FCF $315.22M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$333.35M
EBIT	$456.12M
ROE	26%
ROA	21%
FCF	$315.22M
Equity	$1.29B
Growth Stability	1
PE	15.34
PEG	7.28
PB	3.96
P/FCF	16.22
P/S	3.4
Price/Cash	0.08
Debt/Equity	0.22
Debt/FCF	0.92
Net Margins	20%
Gross Margins	83%
Op. Margins	30%
Earnings CAGR	0%
Sales Growth YoY	-1%
Sales Growth QoQ	-5%
Sales CAGR	9%
FCF CAGR	12%
Equity CAGR	-1%
Earnings Stability	0
Earnings Growth YoY	93%
Earnings Growth QoQ	1%

Earnings CAGR 5Y	2%
Sales CAGR 5Y	8%
FCF CAGR 5Y	46%
Equity CAGR 5Y	4%
Earnings CAGR 3Y	16%
Sales CAGR 3Y	16%
FCF CAGR 3Y	91%
Equity CAGR 3Y	9%
Market Cap	$5.11B
Revenue	$1.51B
Assets	$2.16B
Total Debt	$288.82M
Cash	$396.29M
Shares Outstanding	161.78M
EV	5.01B
Earnings Score	6%
Moat Score	96%
Safety Score	96%
Final Score	66%
Working Capital	1.11B
Current Ratio	3.45
Gross Profit	$1.25B
Shares Growth 3y	-17%
Equity Growth QoQ	1%
Equity Growth YoY	-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

SEC Filings

Direct access to Alkermes Plc. (ALKS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Alkermes Plc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Alkermes Plc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Alkermes Plc. Discounted Cash Flow

Fully customizable DCF calculator online for Alkermes Plc..

Years

Calculation mode

= $7.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$315M	$354M	$398M	$447M	$502M	$564M	$633M	$711M	$799M	$897M	$1B	$10B
DCF		$322M	$329M	$336M	$343M	$350M	$357M	$365M	$373M	$381M	$389M	$3.9B
Value	$7.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-5%	-36%	-28%	-17%	-13%	-17%	-11%	-4%	-14%	21%	20%
ROA	-	-11%	-12%	-7%	-5%	-10%	-5%	-1%	-7%	20%	21%
ROE	-	-17%	-17%	-13%	-12%	-18%	-10%	-4%	-15%	30%	26%

Good Net Margins (19.56%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-4.46	-2.67	-8.76	9.36	-14.69	6.77	4.01	-17.04	0.82	0.92
Debt over Equity	0.26	0.32	0.24	0.23	0.24	0.26	0.26	0.27	0.28	0.24	0.22
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (0.92)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.22)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	2%	19%	21%	21%	7%	-11%	13%	-5%	50%	8%
Earnings YoY growth	-	656%	-8%	-24%	-12%	41%	-44%	-57%	229%	-325%	2%
Equity YoY growth	-	-6%	-8%	-1%	-3%	-7%	-2%	4%	-6%	15%	4%
FCF YoY growth	-	314%	15%	-70%	-193%	-163%	-315%	81%	-123%	-2K%	46%